{"entity":{"id":"nct05455619","kind":"trial","name":"Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer","aka":[],"tldr":"A phase 1/2 trial of Evexomostat in advanced solid tumours, run by SynDevRx, Inc., now recruiting.","summary":"Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer is a phase 1/2 interventional study registered as NCT05455619 by SynDevRx, Inc., with 52 participants planned, started 2022-08-26 and due to reach its primary completion in 2026-12. Interventions recorded: Evexomostat.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05455619","url":"https://clinicaltrials.gov/study/NCT05455619"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05455619","phase":"1/2","setting":"Study to Assess the Safety and Efficacy of Evexomostat (SDX-7320) in Combination With A PI3K or Akt Inhibitor Plus Fulvestrant in Patients With HR+, HER2-, Metastatic Breast Cancer With PI3K Pathway Alteration(s)","sponsor":"SynDevRx, Inc.","enrolled":52,"outcomes":[]},"route":"/trials/nct05455619/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"evexomostat","kind":"drug","name":"Evexomostat","route":"/drugs/evexomostat/"}]}}